Bruna Cerbelli

TL;DR: The preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy, and the metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked “indicators” of early progressor and long responder patients.

TL;DR: Preliminary results suggest the possibility of using anti-PD-1 plus IDO inhibitor in those patients with high level of kyn/trp ratio, associated with response to immunotherapy, and could predict resistance to anti- PD-1 treatment.

TL;DR: It is shown that mtDNA depletion is a constant feature of both conditions and characterized also the end-stage phase of cardiomyopathies due to a primary mtDNA defect.

TL;DR: Different mechanisms could be involved in sex differences with regard to immunotherapy and these differences could be relevant to identify immunological targets in order to draw studies exploring novel combinations of immunotherapy agents.

TL;DR: Nonischemic left ventricular scar (NLVS) is a pattern of myocardial injury characterized by midventricular and/or subepicardial gadolinium hyperenhancement at cardiac magnetic resonance, in absence of significant coronary artery disease.